Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
741 Leser
Artikel bewerten:
(2)

Golden Developing Solutions, Inc: Golden Developing Solutions Inc Announces December 2022 Sales Exceed $5.6 Million

Finanznachrichten News

The Company Is Also Expecting An Additional Bump In Revenues Of 35 To 40% Upon Completion of 'Onboarding' Its Largest Customer

Also Issues Update Of State Of Its Recent Acquisitions Of Revenue Producing Pharmacies

FORT LAUDERDALE, FL / ACCESSWIRE / February 7, 2023 / Golden Developing Solutions Inc. (OTC Pink:DVLP), is a holding company in the Health and Wellness marketplace, with a focus on acquiring companies/pharmacies delivering pharmaceuticals and specialty medicines with rapid delivery services and adequate medical support in the United States today released an update to shareholders and the market, discussing anticipated revenue matters and the state of previously announced acquisitions.

The Company has achieved unaudited December 2022 sales of $5,658,865.07 with the largest customer still to be onboarded. With this addition we are at our targeted run rate from the acquisitions.

It also expects significant increase in revenues after the 4 previously announced acquisitions are fully transitioned. During this final processes of transitioning and onboarding customers we expect a brief dip in Q1 sales followed by a robust rebound and acceleration. After completed, the Company will again begin to acquire more acquisitions in the Specialty Pharmacy market, which also will become another event that should further increase Company revenues, helping it reach its 2023 goals.

Stavros Triant, CEO of DVLP, said: "First of all, we are happy to see December sales exceeded $5.6 million… along with the final customer onboarding would have easily hit our 2022 monthly run rate. We will finish the transitions in Q1 and begin to grow organically, as well as continue our acquisition strategy."

He continued: "We are holding off closing several targeted additional acquisitions until we complete the state, federal, vendor and other rules, regulations and transitions of the 4 we have already acquired. One of the hurdles was that audit work on acquisitions was behind schedule due to proprietary software reporting systems of third parties. We have concluded what we will need to finish these and take appropriate measures if further time is needed to complete."

We will focus on clearing all the hurdles that accompany these types of acquisitions. Because such deals are complicated and that we are doing 4 of these at the same time, its taken a little longer than expected… but we feel that we are on track to garner every single approval required in the very near future."

He concluded: "We are very excited about the business model, the industry, and our future plans. The demand for product and the ability to scale are very promising."

The Company also is updating its website (https://goldendeveloping.com) to include more information for the public, investors and shareholders. Updates will be provided in a timely manner.

About Golden Developing Solutions Inc. (OTC Pink:DVLP):

Golden Developing Solutions is a public online health and wellness start-up company with a focus on delivering specialty medicine with rapid delivery services and adequate medical support in the United State. The recent 4 specialty pharmacy acquisitions in 2022 have capacitated the company's service offerings to the State of Michigan and Florida with a consolidated revenue of $100M.

We aim to position ourselves to build shareholder value by setting the highest standards in service, reliability, and safety in our rapidly growing industry.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors are encouraged to review the Company's filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced herein are not incorporated into this press release.

Corporate Contact:

We encourage our shareholders to follow our Twitter account @OTC_DVLP
Stavros Triant
stavros@goldendeveloping.com

Go to: www.goldendeveloping.com

SOURCE: Golden Developing Solutions, Inc

View source version on accesswire.com:
https://www.accesswire.com/738374/Golden-Developing-Solutions-Inc-OTCDVLP-Announces-December-2022-Sales-Exceed-56-Million

© 2023 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.